KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant and adjuvant pembrolizumab in combination with chemotherapy compared to chemotherapy alone. Methods:The trial enrolled participants […]
Tag: NSCLC
ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC
2017 ALEX TRIAL Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer international, open-label, randomised phase 3 trial Σ Objective: To compare alectinib (600 mg twice daily) with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. 303 patients Participants > 18 years of age, ALK-positive advanced NSCLC, ECOG […]